sST2 and CA125 identify distinct biological phenotypes and predict one-year mortality in very old patients hospitalised for decompensated HFpEF

Background: Risk stratification remains challenging in very old patients hospitalised for decompensated heart failure with preserved ejection fraction (HFpEF). Soluble suppression of tumorigenicity 2 (sST2) and carbohydrate antigen 125 (CA125) reflect complementary pathophysiological domains related to fibro-inflammatory stress and systemic congestion. We evaluated whether their combined assessment identifies distinct prognostic phenotypes. Methods Prospective observational cohort of 175 consecutive patients aged ≥ 80 years admitted for decompensated HFpEF. Four phenotypes were defined by sST2 (cut-off 35 ng/mL) and CA125 (cut-off 35 U/mL): both low, sST2 high only, CA125 high only, and both high. Primary endpoint was one-year all-cause mortality. Results Among 164 patients with complete biomarker data, one-year mortality ranged from 18% in the dual-low phenotype to 43% in the dual-high phenotype, with significant differences across phenotypes (log-rank p = 0.013). After multivariable adjustment, the both-high phenotype was associated with higher mortality compared with the both-low phenotype (HR 2.43, 95% CI 1.01–5.85; p = 0.048). Frailty and lower systolic blood pressure were also independent predictors, whereas BNP was not. When modelled continuously, sST2 was independently associated with mortality (HR 1.51 per SD, 95% CI 1.12–2.05; p = 0.007), with no evidence of non-linearity. Neither rehospitalisation nor the composite endpoint differed significantly across phenotypes. Conclusions Combined assessment of sST2 and CA125 identified distinct prognostic phenotypes in very old patients hospitalised for decompensated HFpEF. Concurrent elevation of both biomarkers was associated with higher one-year mortality, supporting further evaluation of multidimensional biomarker phenotyping in this understudied population.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11455019/v1
Primary Topic
Heart Failure Treatment and Management
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

sST2 and CA125 identify distinct biological phenotypes and predict one-year mortality in very old patients hospitalised for decompensated HFpEF

Pau Llàcer, François Croset, Nuria Bara Ledesma, Miriam Menacho Román et al.
Research Square
Heart Failure Treatment and Management
preprint

sST2 and CA125 identify distinct biological phenotypes and predict one-year mortality in very old patients hospitalised for decompensated HFpEF

Pau Llàcer, François Croset, Nuria Bara Ledesma, Miriam Menacho Román, Luis Manzano, Jorge Campos, Carlos Perez, Cristina Fernández, Bianca Pomana, Esteban Pérez Pisón, Marina Vergara, Martín Fabregate, Alberto Pérez Nieva, Marina García Melero, Andrés Paul Cevallos Castro, Juan Esteban Oyuela Rodriguez, Beatriz Del Hoyo Cuenda, Olivia Sánchez
preprint en

Abstract

Background: Risk stratification remains challenging in very old patients hospitalised for decompensated heart failure with preserved ejection fraction (HFpEF). Soluble suppression of tumorigenicity 2 (sST2) and carbohydrate antigen 125 (CA125) reflect complementary pathophysiological domains related to fibro-inflammatory stress and systemic congestion. We evaluated whether their combined assessment identifies distinct prognostic phenotypes. Methods Prospective observational cohort of 175 consecutive patients aged ≥ 80 years admitted for decompensated HFpEF. Four phenotypes were defined by sST2 (cut-off 35 ng/mL) and CA125 (cut-off 35 U/mL): both low, sST2 high only, CA125 high only, and both high. Primary endpoint was one-year all-cause mortality. Results Among 164 patients with complete biomarker data, one-year mortality ranged from 18% in the dual-low phenotype to 43% in the dual-high phenotype, with significant differences across phenotypes (log-rank p = 0.013). After multivariable adjustment, the both-high phenotype was associated with higher mortality compared with the both-low phenotype (HR 2.43, 95% CI 1.01–5.85; p = 0.048). Frailty and lower systolic blood pressure were also independent predictors, whereas BNP was not. When modelled continuously, sST2 was independently associated with mortality (HR 1.51 per SD, 95% CI 1.12–2.05; p = 0.007), with no evidence of non-linearity. Neither rehospitalisation nor the composite endpoint differed significantly across phenotypes. Conclusions Combined assessment of sST2 and CA125 identified distinct prognostic phenotypes in very old patients hospitalised for decompensated HFpEF. Concurrent elevation of both biomarkers was associated with higher one-year mortality, supporting further evaluation of multidimensional biomarker phenotyping in this understudied population.

Research Square
Hospital Universitario Ramón y Cajal (ES)
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon